Lyell Immunopharma, Inc. (LYEL) vs Sutro Biopharma, Inc. (STRO)
- Lyell Immunopharma, Inc. LYEL 8.12 −0.85%
- Sutro Biopharma, Inc. STRO 10.94 −4.54%
Lyell Immunopharma, Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and Sutro Biopharma, Inc. are of similar size ($200.7M and $190.0M). Lyell Immunopharma, Inc. grew revenue faster over the last twelve months: −55.0% against −56.3%. Sutro Biopharma, Inc. has the higher net margin (−395.3% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 15 metrics below, Sutro Biopharma, Inc. leads on 9 and Lyell Immunopharma, Inc. on 6.
Valuation
Profitability
| Metric | LYEL | STRO | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (949,981.48%) | (319.57%) | 0.00% |
| Net margin | (920,285.19%) | (395.25%) | 0.00% |
| Free cash flow margin | (647,681.48%) | (318.63%) | 0.00% |
| Return on equity | (93.28%) | 266.76% | (56.36%) |
| Return on assets | (71.34%) | (79.08%) | (48.04%) |
| Return on invested capital | (539.53%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack